Indication: Letrozole is approved for the treatment of local or metastatic breast cancer that is hormone receptor positive or has an unknown receptor status in postmenopausal women.
• Letrozole is indicated for
Specification:
Dosage Form: Injection
Active Ingredients:
Route of Administration: Oral
Shelf Life: 18 months
Storage: Sealed
Package:
Place of Origin:
Qualification: Chinese GMP
Product Description
Letroze 2.5mg
Letrozole Film Coated TabletsNon-Steroidal Aromatase Inhibitor
Give your patients a better option to treat breast cancer!INDICATIONS:• Letrozole is approved for the treatment of local or metastatic breast cancer that is hormone receptor positive or has an unknown receptor status in postmenopausal women. • Letrozole is indicated for first-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer. • Letrozole is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. ADVANTAGES:
Treatment extension with Adjuvant Aromatase Inhibitor to 10 years results in significantly higher rates of disease free survival
34% lower risk of disease recurrence. [16] Safe and beneficial for postmenopausal women.
BRIEF PRESCRIBING INFORMATION:
Letroze (letrozole) tablets INDICATIONS AND USAGE: Letroze is an aromatase inhibitor indicated for: (1) Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. (2) Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant Tamoxifen therapy. (3) First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer. DOSAGE AND ADMINISTRATION: Letroze tablets are taken orally without regard to meals: Recommended dose: 2.5 mg once daily. Patients with cirrhosis or severe hepatic impairment: 2.5 mg every other day. DOSAGE FORMS AND STRENGTHS: 2.5 milligram tablets. CONTRAINDICATIONS: Women of premenopausal endocrine status, including pregnant women. WARNINGS AND PRECAUTIONS: Decreases in bone mineral density may occur. Consider bone mineral density monitoring. Increases in total cholesterol may occur. Consider cholesterol monitoring. Fatigue, dizziness and somnolence may occur. Exercise caution when operating machinery. ADVERSE REACTIONS: The most common adverse reactions (>20%) were hot flashes, arthralgia; flushing, asthenia, edema, arthralgia, headache, dizziness, hypercholesterolemia, sweating increased, bone pain; and musculoskeletal These highlights do not include all the information needed to use LETROZE safely and effectively. See full prescribing information for LETROZE. M.R.P: 6,000/- PKR
